Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial

Date Issued
2017-10
Author(s)
Winkelmann, Juliane
Oertel, Wolfgang H.
Virgin, Garth
Roubert, Bernard
Mezzacasa, Anna
DOI
10.1002/mds.27040
Abstract
Compromised iron status is important in restless legs syndrome pathophysiology. We compared the efficacy and tolerability of ferric carboxymaltose (single intravenous dose) versus placebo for restless legs syndrome treatment in iron-deficient nonanemic patients.
File(s)
No Thumbnail Available
Name

Trenkwalder_et_al-2017-Movement_Disorders.pdf

Size

359.69 KB

Checksum (MD5)

65ca4add17cb21b797e7f47316422471

Download